Year: 2013
Type: review
Abstract: Dipeptidyl peptidase-4 (DPP-4) is a membrane-associated peptidase, also known as CD26. DPP-4 has widespread organ distribution throughout the body and exerts pleiotropic effects via its peptidase activity. A representative target peptide is glucagon-like peptide-1, and inactivation of glucagon-like peptide-1 results in the development of glucose intolerance/diabetes mellitus and hepatic steatosis. In addition to its peptidase activity, DPP-4 is known to be associated with immune stimulation, binding to and degradation of extracellular matrix, resistance to anti-cancer agents, and lipid accumulation. The liver expresses DPP-4 to a high degree, and recent accumulating data suggest that DPP-4 is involved in the development of various chronic liver diseases such as hepatitis C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma. Furthermore, DPP-4 occurs in hepatic stem cells and plays a crucial role in hepatic regeneration. In this review, we described the tissue distribution and various biological effects of DPP-4. Then, we discussed the impact of DPP-4 in chronic liver disease and the possible therapeutic effects of a DPP-4 inhibitor.
Authors: Minoru Itou, Takumi Kawaguchi, Eitaro Taniguchi, Michio Sata
Institution: Kurume University
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Keywords: dipeptidyl peptidase IV, CD26, chronic liver disease, glucagon-like peptide-1, DPP-4 inhibitors, non-alcoholic fatty liver disease, hepatitis C virus, hepatocellular carcinoma, liver regeneration, hepatic stem cells, hepatic steatosis, extracellular matrix, immunostimulation, lipid accumulation, diabetes mellitus
Open Access status: hybrid
OpenAlex ID: W2138197806
